The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

AstraZeneca and Daiichi Sankyo have chalked up another positive trial for their HER2-directed antibody-drug conjugate Enhertu in early breast cancer, this time in the 'post-neoadjuvant' setting. The ...

AstraZeneca and Daiichi Sankyo pushed back the readout of their trial of Datroway in triple-negative breast cancer (TNBC) patients ineligible for frontline immunotherapies, but the result has been ...